Murine recombinant interleukin 1 was injected intra-articularly into mice. It induced a clear effect on patellar cartilage within 24 hours. A low dose of interleukin 1 (1 ng) elicited a significant reduction in [35S]sulphate incorporation (50%) into proteoglycans and an accelerated breakdown (twofold) of 35S prelabelled proteoglycan. Proteoglycan breakdown returned to normal rates (-100/o/day) 48 hours after a single interleukin 1 injection. Recovery of proteoglycan synthesis was delayed by up to 72 hours, however, which implies that repair of the depleted cartilage matrix is retarded. Interleukin 1 induced only minor joint inflaation, too slight to be held responsible for the strong suppression of proteoglycan synthesis. Vehement joint inflammation was found after repeated interleukin 1 injections. The plasma extravasation and massive infiltration and exudation of leucocytes, predominantly polymorphonuclear leucocytes, were not a mere summation of single interleukin 1 effects, but point to interleukin 1 induced local hypersensitivity. The cartilage matrices of patelia and femur were heavily depleted. [ig/ml. The recombinant interleukin 1 preparation was stored at -20°C and showed consistent lymphocyte activating factor activity over the period studied.
Interleukin 1 is a 17 kilodalton soluble unglycosylated protein, secreted by activated cells of mononuclear origin. Two forms have been described, interleukin la and interleukin 1f, which are related proteins that bind to the same receptor and show roughly the same biological effects.1-3 This ubiquitous mediator displays many inflammatory and immunoregulatory activities.`After systemic administration interleukin 1 gave rise, for example, to an acute phase response, enhanced immunoglobulin production, and protection against bacterial injury.-'l Apart from systemic effects, related to high concentrations of circulating interleukin 1 during inflammatory processes," interleukin 1 may also play a more direct part in local inflammatory events. It has been shown that interleukin 1 injected into the skin attracted neutrophils, leading to microvascular injury. [12] [13] [14] Moreover, interleukin 1 enhanced the binding oflymphocytes to endothelial cells and promoted chemotaxis of these cells.'520 Recombinant interleukin 1 injected directly into rabbit knee joints induced only minor inflammation,2' but it was highly effective in causing an exacerbation of the arthritic process in a previously injured joint. 22 The important role of interleukin 1 in arthritis is further substantiated by the observation that it is produced by the arthritic synovium23 24 and it can be detected in substantial amounts in synovial fluids.25 29 Whether interleukin 1 is the predominant pathological messenger or only one of many effector cytokines in arthritis is still unknown.
In addition, interleukin 1 Time (h) after IA injection membrane (fig 4) .
In conclusion, the inhibition of proteoglycan synthesis by interleukin 1 must be due to a direct effect on cartilage and was not secondary to inflammation induced by interleukin 1.
INTERLEUKIN la RETENTION IN MURINE KNEE JOINT
The iodinated interleukin 1 Representative experiment in which single and triple (three times on alternate days) interleukin 1 injections were compared for their inflammatory effect, six to 48 hours after the last injection. The joint sections were scored on: infiltration of leucocytes into the synovial membrane, exudation of polymorphonuclear cells into the joint cavity, and the proteoglycan depletion of cartilage matrix. Histological changes were arbitrarily represented as 0=no changes, ± =slight, + =moderate, + + =marked, +++ =strong. Joint swelling was expressed by an enhanced ratio of 'lTc pertechnetate uptake, and significant differences-' p<0-00l-were calculated by Student's t test. Repeated saline injections did not cause an enhanced 9'9Tc ratio. tILI=interleukin 1. The marked depletion of cartilage matrix after repeated interleukin 1 injections as shown by histology (fig 4) is probably the final result of both cumulative breakdown of proteoglycan (18%, table 4) and prolonged suppression of proteoglycan synthesis (50%, table 4). At day 1 after a single interleukin 1 injection about 10% proteoglycan depletion was found, and the lack of clear-cut proteoglycan loss on histological sections taken at that time (fig 4) indicates that this degree of depletion is beyond the detection limit. The marked depletion after repeated interleukin 1 injections must therefore reflect a much higher degree of proteoglycan depletion and this may only be explained by a considerable lackofsufficient resynthesis ofnew proteoglycan. Kinetic studies on this subject are in progress. Earlier studies with purified interleukin 1 preparations given once a day yielded high degrees of proteoglycan depletion,39 40 
